Search results for "ALIM"

showing 10 items of 1991 documents

Brand on the run: mirada semiotica sobre Slow Food

2011

Brand alimentazione testualità semiotica
researchProduct

Evolution of microbiological and chemical parameters during red wine making with extended post-fermentation maceration.

2014

Abstract The aim of the present work was to investigate the microbiological, chemical, and sensory characteristics of red wine subjected to post-fermentation maceration that was extended to 90 days. For this purpose, the ‘Aglianico di Taurasi’ grape was used as a case study. The total yeast concentration increased until day 40 of maceration and decreased thereafter, whereas the concentration of lactic acid bacteria slightly increased. Dekkera/Brettanomyces spp. and acetic acid bacteria were not detected. The yeast community was composed of Saccharomyces cerevisiae, Zygosaccharomyces bisporus, Metschnikowia pulcherrima, Hanseniaspora guilliermondii, Hanseniaspora uvarum, Pichia guilliermondi…

BrettanomycesFood HandlingColony CountColony Count MicrobialWineSaccharomyces cerevisiaeMicrobiologyTimechemistry.chemical_compoundMicrobialYeastsBotanyLactic acid bacteriaMaceration (wine)Lactic acid bacteria; Polyphenols; Prolonged post-fermentation maceration; Red wine production; Saccharomyces cerevisiae; Yeasts; Acetic Acid; Alcohols; Colony Count Microbial; Humans; Mycological Typing Techniques; Polyphenols; Saccharomyces cerevisiae; Taste; Time; Vitis; Wine; Yeasts; Fermentation; Food Handling; Food Microbiologyred wine long maceration microorganismsHumansVitisFood scienceRed wine productionAcetic acid bacteriaMycological Typing TechniquesAcetic AcidWinebiologyProlonged post-fermentation macerationfood and beveragesPolyphenolsSettore AGR/15 - Scienze E Tecnologie AlimentariGeneral Medicinebiology.organism_classificationchemistryAlcoholsTasteFermentationFood MicrobiologyHanseniaspora guilliermondiiFermentationMalic acidMetschnikowia pulcherrimaSettore AGR/16 - Microbiologia AgrariaFood ScienceInternational journal of food microbiology
researchProduct

Microwave and optical data fusion for global mapping of soil moisture at high resolution

2018

After more than 8 years in orbit the Soil Moisture and Ocean Salinity (SMOS) satellite is still in good health and several algorithms for improving its spatial resolution have been proposed and validated in a variety of catchments. However, none of them has yet been applied at the global scale. In this article we present: i) a review of the latest SMOS-BEC downscaling algorithm, which allows for its global application using an adaptive moving window and ii) a thorough validation of the resulting maps over two in-situ networks: REMEDHUS in Spain and OzNet in Australia. The proposed algorithm combines SMOS brightness temperatures (at ~40 km spatial resolution), and MODIS-derived Land Surface …

BrightnessTeledetecció010504 meteorology & atmospheric sciences0211 other engineering and technologies02 engineering and technology01 natural sciences:Enginyeria agroalimentària::Ciències de la terra i de la vida::Edafologia [Àrees temàtiques de la UPC]In-situ stationsDownscalingImage resolutionWater content021101 geological & geomatics engineering0105 earth and related environmental sciencesRemote sensingAdaptive moving windowRemote sensing:Enginyeria de la telecomunicació::Radiocomunicació i exploració electromagnètica::Teledetecció [Àrees temàtiques de la UPC]Orbit (dynamics)Environmental scienceERA5SatelliteSoil moistureSòls -- HumitatScale (map)MicrowaveDownscalingSMOS
researchProduct

Is TNF-α really involved in giant cell arteritis pathogenesis?

2013

Giant cell arteritis (GCA) is the most frequent vasculitis in people >50 years, and glucocorticoids (GC) remain the cornerstone of the treatment. However, this long-term treatment is responsible for numerous GC-related complications.1 Thus, reliable GC-sparing drugs need to be explored. Seror et al 2 have recently reported the inefficacy of adalimumab, a humanised anti-TNF-α therapy, as a GC-sparing drug in the treatment of GCA. These clinical results contrast with previous studies reporting a production of TNF-α by giant cells and macrophages in GCA lesions.3 However, recent advance in the knowledge of GCA pathogenesis have shown that macrophages and giant cells are not involved in the fir…

CD4-Positive T-LymphocytesMaleImmunologyGiant Cell ArteritisGeneral Biochemistry Genetics and Molecular BiologyPathogenesisRheumatologyimmune system diseasesAdalimumabImmunology and AllergyMedicineHumanscardiovascular diseasesskin and connective tissue diseasesAgedAged 80 and overbusiness.industryTumor Necrosis Factor-alphaMiddle Agedmedicine.diseaseGiant cell arteritisGiant cellImmunologycardiovascular systemTumor necrosis factor alphaFemalebusinessVasculitismedicine.drugAnnals of the rheumatic diseases
researchProduct

Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal…

2011

Background & Aims The anti–tumor necrosis factor (TNF) antibodies infliximab, adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn's disease. Here, we assessed the effects of anti-TNF antibodies on apoptosis in inflammatory bowel disease (IBD). Methods CD14 + macrophages and CD4 + T cells were isolated from peripheral blood and lamina propria mononuclear cells from patients with IBD and control patients. Cell surface markers and apoptosis were assessed by immunohistology and fluorescence-activated cell sorting techniques. Results Lamina propria CD14 + macrophages showed significantly more frequent and higher membrane-bound TNF (mTNF) expression than CD4 + T cells in IBD…

CD4-Positive T-LymphocytesMaleNecrosisCD14Anti-Inflammatory AgentsLipopolysaccharide ReceptorsApoptosisEnzyme-Linked Immunosorbent AssayBiologyAntibodies Monoclonal HumanizedReal-Time Polymerase Chain ReactionPeripheral blood mononuclear cellPolyethylene GlycolsImmunoglobulin Fab FragmentsYoung AdultmedicineHumansReceptors Tumor Necrosis Factor Type IIAntigen-presenting cellAgedLamina propriaHepatologyCluster of differentiationTumor Necrosis Factor-alphaMacrophagesGastroenterologyAdalimumabAntibodies MonoclonalMiddle AgedFlow CytometryInflammatory Bowel DiseasesInfliximabmedicine.anatomical_structureApoptosisCase-Control StudiesImmunologyCertolizumab PegolTumor necrosis factor alphaFemalemedicine.symptomGastroenterology
researchProduct

CISPLATIN (C) AND ALIMTA (A) WITH PANITUMUMAB FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC): A PHASE I-DOSE FINDING STUDY.

2012

Background The treatment of NSCLC is rapidly changing since new drugs are becoming available. Recently, CA has become a standard for the first line treatment of NS-NSCLC. Previous clinical studies have shown that anti-EGFR MoAb may be added to chemotherapy, but the identification of a molecular signature can predict their activity and better define their true role. Aims In absence of data about the MTD of Panitumumab (a MoAb targeting the EGFR, potentially active in NS-NSCLC) when associated to chemotherapy, we decided to assess the optimal dose of panitumumab in combination with CA. Moreover, in view of a future phase II study, all pts will be studied for the following molecular characteri…

CISPLATINSettore MED/06 - Oncologia MedicaALIMTAPANITUMUMAB
researchProduct

METODI FISICO E BIOLOGICO DI IDENTIFICAZIONE DI ALIMENTI IRRADIATI CONTENENTI CELLULOSA ATTRAVERSO L'USO DELLA DNA COMET ASSAY E DELLE SPETTROSCOPIA …

2013

COMET ASSAYALIMENTI IRRADIATISPETTROSCOPIA ESRSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Esperienze di vinificazione di uve Grillo con protezione del mosto dalle ossidazioni

2009

CV Grillo vinificazioni in riduzione aromi tioliciSettore AGR/15 - Scienze E Tecnologie Alimentari
researchProduct

Búsqueda de nuevos ingredientes bioactivos en obesidad para el diseño de nuevos alimentos funcionales, en base a la demanda del consumidor

2015

La innovación tecnológica en materia de salud ha sido un campo ampliamente estudiado y sigue siendo un foco de interés económico reiterado y prioritario. La alimentación es uno de los hábitos que más repercusión tienen en el estado de salud y en la prevención de determinadas enfermedades lo que influye cada vez más en los hábitos de compra de los consumidores (Niva M., 2007, Bech-Larsen T et al., 2007, Jones PJ et al., 2007, Van Kleef E et al., 2002). Un trastorno de la alimentación puede generar obesidad y con ello el desarrollo de múltiples complicaciones asociadas a la misma. En los últimos años, la Organización Mundial de la Salud (WHO., 2014 y 2015) ha venido alertando de la gran crisi…

Cacaopeptidos bioactivosestudio de mercado:CIENCIAS MÉDICAS ::Ciencias de la Nutrición ::Metabolismo energético [UNESCO]:CIENCIAS TECNOLÓGICAS::Tecnología de los alimentos::Alimentos proteínicos [UNESCO]UNESCO::CIENCIAS MÉDICAS ::Ciencias de la Nutrición ::Metabolismo energéticolipasa pancreáticaUNESCO::CIENCIAS TECNOLÓGICAS::Tecnología de los alimentos::Alimentos proteínicosC.elegansobesidad
researchProduct

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1

2014

Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system. The recent development of new antibodies against immune check points may help to overcome the immune silencing induced by human tumors. Some of these antibodies have already been approved for treatment of various solid tumor entities. Interestingly, targeting antibodies may be combined with standard chemotherapy or radiation protocols. Furthermore, recent evidence indicates that intratumoral (it) or intravenous (iv) injections of replicative oncolytic viruse…

Cancer ResearchParvovirus H-1medicine.medical_treatmentautonomous parvovirusReview Articlelcsh:RC254-282JX-594Immune systemAntigenmedicineDentritic cellsdendritic cellsVirotherapybusiness.industryImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virusH-1PVT-VECtalimogene laherparepvecOncologyCTLA-4ImmunologyCTLA-4immunotherapyTalimogene laherparepvecbusinessFrontiers in Oncology
researchProduct